An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

— MIRANTIBUS  

Official title:

An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05385744
• Other study ID #: BCD-132-4
• Status: Recruiting
• Phase: Phase 3
• Start date: April 5, 2021
• Est. completion date: March 2024

Study information

• Verified date: May 2022
• Source: Biocad
• Contact: Daria Bolsun
• Phone: 7 (812) 380 49 33
• Email: bolsun[@]biocad.ru
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Clinical study BCD-132-4/MIRANTIBUS is an international, multicenter, randomized, double-blind, double-masked study using an active reference drug (teriflunomide). The goal of the study is to evaluate the efficacy and safety of BCD-132 in the treatment of patients with relapsing multiple sclerosis.

Description:

Clinical study No. BCD-132-4/MIRANTIBUS is an international, multicenter, randomized, double-blind, double-masked study using an active reference drug (teriflunomide). The goal of the study is to evaluate the efficacy and safety of BCD-132 in the treatment of patients with relapsing multiple sclerosis. The study includes adults with relapsing-remitting multiple sclerosis (according to 2017 revision to the McDonald Diagnostic Criteria for Multiple Sclerosis) and EDSS disability score up to 5.5. Some of the subjects in this study will be patients rolled over from ongoing phase II clinical study No. BCD-132-2; treatment group, individual product kit number (IPKN), stratification factors, order of procedures and timeframes for blinded therapy with a duration of up to 100 weeks will remain the same.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 336
• Est. completion date: March 2024
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Written informed consent for participation in the study;

2. Male and female subjects, 18 to 60 years of age

3. Diagnosis of relapsing multiple sclerosis (according to 2017 revision to the McDonald Diagnostic Criteria for Multiple Sclerosis);

4. Documentary evidence that, at the time of signing the informed consent, the subject

had:

1. at least 1 relapse within the last calendar year (12 months), or

2. 2 relapses within the last 2 years (24 months), or

3. at least 1 T1 gadolinium-enhanced brain lesion on MRI and 1 relapse within 2 calendar years (24 months) prior to signing the informed consent;

5. The subject must be neurologically stable for 30 days prior to signing the informed consent

6. Total EDSS score 0 to 5.5 inclusive

7. Positive anti-Varicella Zoster IgG antibodies according to screening test results;

8. Absence of suicidal ideation and behavior confirmed at screening according to C-SSRS score within 1 month prior to signing the informed consent

9. Willingness of both female and male patients and their sexual partners of childbearing potential to use reliable contraception Exclusion Criteria: Primary progressive MS; Duration of multiple sclerosis for more than 10 years with EDSS =2.0 according to screening assessments; Other disorders (besides multiple sclerosis), which could affect the assessment of symptom severity for the primary disease A relapse during screening period ; Use of systemic corticosteroids for 30 days prior to signing the informed consent; Disorders, besides multiple sclerosis, requiring long-term systemic therapy with corticosteroids and/or immunosuppressants; Heart failure (NYHA functional class III/IV); encephalopathy, lactic acidosis, MELAS syndrome), neuromyelitis optica, sarcoidosis; Diagnosis of HIV, hepatitis B, hepatitis C, or syphilis ; Increased TTG levels at least two times the upper limit of normal on screening tests; Suicidal ideation and/or behavior History of severe depression Pregnancy, breastfeeding, or intention to become pregnant at any point throughout the study period; Prior use of anti-B cell therapies Intolerance, including hypersensitivity to any component of BCD-132/teriflunomide, premedication drugs, or conditions in which the above drugs are contraindicated in the Investigator's opinion; History of severe allergic or anaphylactic reactions to humanized and/or murine monoclonal antibodies; History of progressive multifocal leukoencephalopathy Known alcohol or drug addiction or signs of current alcohol/drug addiction Inability to follow the procedures specified in the Protocol, as assessed by the Investigator; Contraindications to MRI and administration of gadolinium-based contrast agents: Any current or prior malignancies, except for successfully treated basal cell carcinoma and cervical carcinoma in situ Vaccination within 6 weeks prior to signing the informed consent -

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Biological:
• BCD-132
anti-CD20 monoclonal antibody

Drug:
• Teriflunomide
Teriflunomide 14 mg

Locations

Country	Name	City	State
Russian Federation	State Budgetary Healthcare Institution of the Moscow Region M.F. Vladimirsky Moscow Regional Research and Clinical Institute	Moscow

Sponsors (1)

Lead Sponsor	Collaborator
Biocad

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Annualized relapse rate	Annualized relapse rate at 48 weeks after the randomization of the last patient in the study	week 48
Secondary	Proportion of patients with persistent progression	Persistent progression is defined as an increase in the EDSS score from Visit 1 by at least 1.0 in patients with a score >0 and =5.5 at the first visit and by at least 1.5 in patients with a score of 0 at the first visit	week 48
Secondary	Total number of T1 Gd+ lesions	Total number of T1 Gd+ lesions (per scan) detected on brain MRI;	week 48
Secondary	CUA	Combined unique active lesions	week 48
Secondary	Proportion of patients without contrast-enhancing lesions	Proportion of patients without contrast-enhancing lesions	week 48
Secondary	Number of new or enlarged T2 lesions	Number of new or enlarged T2 lesions	week 48
Secondary	Proportion of patients without new or enlarged T2 lesions	Proportion of patients without new or enlarged T2 lesions	week 48
Secondary	Changes in the neurologic deficit according to EDSS score	Changes in the neurologic deficit according to Expanded Disability Status Scale	week 48
Secondary	Annualized relapse rate	Mean annualized relapse rate	week 48
Secondary	Proportion of patients with adverse reactions		week 48
Secondary	Proportion of patients with serious adverse reactions		week 48